


In the Claims

The following amendments are made with respect to the claims in the International application PCT/GB2005/001031.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (currently amended). ~~Use of a~~ A compound for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, wherein the compound is of formula (I)



wherein R_1 is H or Me;

R_2 is H or alkyl and R_3 is H or Me, or R_2 and R_3 are $-CH_2-$ thereby forming a ring;

n is 0 to 2;

X is CH_2 or O; and

the two benzene rings are each optionally substituted with OH, OMe, halogen, $NHCHO$, $NHSO_2Me$, $CONH_2$, $SOMe$, OCH_2O or CH_2OH .

2 (currently amended). ~~[[Use]]~~ The method according to claim 1, wherein the condition is a chronic degenerative disease such as rheumatoid arthritis, osteoarthritis or osteoporosis.

3 (currently amended). ~~[[Use]]~~ The method according to claim 1, wherein the condition is a chronic demyelinating disease such as multiple sclerosis.

4 (currently amended). [[Use]] The method according to claim 1, wherein the condition is a respiratory disease such as asthma or chronic obstructive pulmonary disease.

5 (currently amended). [[Use]] The method according to claim 1, wherein the condition is an inflammatory bowel disease (IBD) such as ulcerative colitis or Crohn's disease.

6 (currently amended). [[Use]] The method according to claim 1, wherein the condition is a dermatological condition such as psoriasis, scleroderma or atopic dermatitis.

7 (currently amended). [[Use]] The method according to claim 1, wherein the condition is a dental disease such as periodontal disease or gingivitis.

8 (currently amended). [[Use]] The method according to claim 1, wherein the condition is diabetic nephropathy, lupus nephritis, IgA nephropathy or glomerulonephritis.

9 (currently amended). [[Use]] The method according to claim 1, wherein the condition is systemic lupus erythematosus (SLE).

10 (currently amended). [[Use]] The method according to claim 1, wherein the condition is graft vs host disease.

11 (currently amended). [[Use]] The method according to claim 1, wherein the condition is a pain condition.

12 (currently amended). [[Use]] The method according to claim 11, wherein the pain condition is chronic pain such as chronic back pain, malignant pain, chronic headache (including migraine and cluster headaches) or arthritic pain).

13 (currently amended). [[Use]] The method according to claim 11, wherein the pain condition is acute pain such as post-operative pain, post-traumatic pain or acute disease-induced pain.

14 (currently amended). ~~[[Use]]~~ The method according to claim 11, wherein the pain condition is neuropathic pain.

15 (currently amended). ~~Use according to any preceding claim~~ The method according to claim 1, wherein the compound is selected from bufeniode, denopamine, fenoterol, ifenprodil, isoxsuprine, labetalol, medroxalol, mesuprine, nyldrin, protokylol, ractopamine, ritodrine, salmefamol and sulfinalol.

16 (currently amended). ~~Use according to any preceding claim~~ The method according to claim 1, wherein the compound is chiral and is in the form of the enantiomer or diastereomer that has relatively little or no activity at the α or β adrenoceptor.

17 (currently amended). ~~Use according to any preceding claim~~ The method according to claim 1, wherein the patient to be treated is also administered another therapeutic agent selected from corticosteroids, cytotoxics, antibiotics, immunosuppressants, non-steroidal anti-inflammatory drugs, narcotic analgesics, local anaesthetics, NMDA antagonists, neuroleptics, anti-convulsants, anti-spasmodics, anti-depressants and muscle relaxants.